{"id":"NCT00848536","sponsor":"Alcon Research","briefTitle":"Efficacy Study of Travoprost APS Versus TRAVATAN","officialTitle":"A Multi-Center, Double-Masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATANÂ® in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2010-01","completion":"2010-01","firstPosted":"2009-02-20","resultsPosted":"2011-03-08","lastUpdate":"2012-04-06"},"enrollment":371,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Open Angle Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution","otherNames":[]},{"type":"DRUG","name":"Travoprost 0.004% (BAK-preserved) Eye Drops, Solution","otherNames":[]}],"arms":[{"label":"TRAVATAN APS","type":"EXPERIMENTAL"},{"label":"TRAVATAN","type":"ACTIVE_COMPARATOR"}],"summary":"A Multi-Center Double-masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATAN in Patients with Open-angle Glaucoma or Ocular Hypertension","primaryOutcome":{"measure":"Mean Intraocular Pressure at 9:00 am","timeFrame":"3 months (measured at 9:00 am)","effectByArm":[{"arm":"TRAVATAN APS","deltaMin":17.9,"sd":0.25},{"arm":"TRAVATAN","deltaMin":18.1,"sd":0.25}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":185},"commonTop":["Ocular hyperaemia","Eye irritation","Conjunctival hyperaemia"]}}